Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220034/S010

LIAISON Biotrin Parvovirus B19 IgG Plus; LIAISON Biotrin Control Parvovirus B19 IgG Plus

DiaSorin, Inc. · Decision date Aug 18, 2026

FDA DECISIONP220034/S010

What did the FDA approve?

FDA records P220034/S010 as a supplement to PMA P220034, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 18, 2026.

FDA approval order statement

Approval of the LIAISON diluteX as an accessory to LIAISON XL analyzer for use with the LIAISON Biotrin Parvovirus B19 IgG Plus assay
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Microbiology
Decision date
Aug 18, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P220034/S010
Regulatory pathway
PMA supplement
Product code
MYL
Decision code
APPR
Decision date
Aug 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGG.

Product code
MYL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P220034/S007 · Related supplement

    LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus

  2. P220034/S008 · Related supplement

    LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus

  3. P220034/S010 received

    Application receipt date recorded by FDA.

  4. P220034/S011 · Related supplement

    LIAISON Biotrin Parvovirus B19 IgG Plus, LIAISON Biotrin Control Parvovirus B19 IgG Plus

  5. P220034/S010 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P220034. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220034

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

DiaSorin, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1951 Northwestern Ave., Stillwater, MN, 55082

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records